# Phase 2 Lung Diseases, Interstitial trials: 30 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials in phase 2 for Lung Diseases, Interstitial that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lung Diseases, Interstitial trials: 30 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lung-diseases-interstitial

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 30
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 15, 2026 | NCT07821398 | Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821398) |
| July 30, 2026 | NCT07737249 | Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Interstitial Lung Diseases | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737249) |
| May 7, 2026 | NCT07572383 | Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Interstitial Lung Disease, Pulmonary Fibrosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572383) |
| March 23, 2026 | NCT07486869 | Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | University of Miami | Phase 2 | Recruiting | Dermatomyositis, Dermatomyositis Sine Myositis, Dermatomyositis With Myopathy, Dermatomyositis With Respiratory... | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486869) |
| March 16, 2026 | NCT07473700 | Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease | Tectonic Operating Company, Inc. | Phase 2 | Recruiting | Hypertension, Pulmonary, Lung Diseases, Interstitial | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473700) |
| March 2, 2026 | NCT07443436 | Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Interstitial Lung Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443436) |
| February 19, 2026 | NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420439) |
| February 9, 2026 | NCT07398287 | Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease | Region Skane | Phase 2 | Recruiting | Interstitial Lung Disease (ILD) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398287) |
| January 12, 2026 | NCT07333183 | A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmovant, Inc. | Phase 2 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333183) |
| January 7, 2026 | NCT07323732 | A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | NSCLC, NSCLC, Stage I, NSCLC Stage II, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07323732) |
| December 16, 2025 | NCT07284459 | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284459) |
| September 16, 2025 | NCT07175038 | A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung... | AllRock Bio, Inc. | Phase 2 | Recruiting | Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175038) |
| July 2, 2025 | NCT07047690 | A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis | Galderma R&D | Phase 2 | Recruiting | Systemic Sclerosis | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047690) |
| May 13, 2025 | NCT06968845 | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Rein Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06968845) |
| December 3, 2024 | NCT06714123 | Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease | Vejle Hospital | Phase 2 | Recruiting | Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06714123) |
| March 22, 2024 | NCT06325696 | H01 in Adults With Interstitial Lung Disease (The SOLIS Study) | National Institute of Environmental Health Sciences (NIEHS) | Phase 2 | Recruiting | Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06325696) |
| January 8, 2024 | NCT06195072 | Platform Clinical Study for Conquering Scleroderma | Scleroderma Research Foundation, Inc. | Phase 2 | Recruiting | Interstitial Lung Disease Due to Systemic Disease, Scleroderma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06195072) |
| September 25, 2023 | NCT06053164 | Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease | University of Alberta | Phase 2 | Recruiting | Fibrotic Interstitial Lung Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06053164) |
| September 15, 2023 | NCT06038630 | 129Xe MRI Cardiopulmonary | Sponsor not shown (see the record) | Phase 2 | Recruiting | Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia... | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06038630) |
| August 14, 2023 | NCT05986318 | Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Lung Cancer, Interstitial Lung Disease | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05986318) |
| August 4, 2023 | NCT05975983 | Study Evaluating INS018\_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis | InSilico Medicine Hong Kong Limited | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05975983) |
| June 7, 2023 | NCT05892614 | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung... | aTyr Pharma, Inc. | Phase 2 | Recruiting | Interstitial Lung Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05892614) |
| April 5, 2023 | NCT05798923 | LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | IRulya Therapeutics Inc. | Phase 2 | Recruiting | Pulmonary Hypertension Due to Lung Diseases and Hypoxia | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05798923) |
| March 27, 2023 | NCT05785065 | Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Recruiting | Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05785065) |
| June 14, 2022 | NCT05417776 | Collagen-targeted PET Imaging for Early Interstitial Lung Disease | Massachusetts General Hospital | Phase 2 | Recruiting | Interstitial Lung Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05417776) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Pulmovant, Inc. | 1 |
| AllRock Bio, Inc. | 1 |
| University of Alberta | 1 |
| Scleroderma Research Foundation, Inc. | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| Massachusetts General Hospital | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| IRulya Therapeutics Inc. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Contineum Therapeutics | 1 |
| National Institute of Environmental Health Sciences (NIEHS) | 1 |
| Peking Union Medical College Hospital | 1 |
| aTyr Pharma, Inc. | 1 |
| Vejle Hospital | 1 |
| Mayo Clinic | 1 |
| Region Skane | 1 |
| [Galderma R&D](https://specstream.ai/data/clinical-trials/company/galderma-r-and-d) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Tectonic Operating Company, Inc. | 1 |
| Intergroupe Francophone de Cancerologie Thoracique | 1 |
| University of Miami | 1 |
| Rein Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 20 |
| Canada | 5 |
| France | 4 |
| Poland | 4 |
| Australia | 3 |
| Germany | 3 |
| Spain | 3 |
| United Kingdom | 3 |
| Denmark | 2 |
| Serbia | 2 |
| South Korea | 2 |
| Romania | 2 |
| Italy | 1 |
| Latvia | 1 |
| Argentina | 1 |
| Belgium | 1 |
| Chile | 1 |
| Greece | 1 |
| Israel | 1 |
| New Zealand | 1 |
| Peru | 1 |
| Portugal | 1 |
| Taiwan | 1 |
| China | 1 |
| Estonia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
- [Cement suppliers in the United States](https://specstream.ai/data/businesses/cement-suppliers/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
- [Scandinavian restaurants in the United States](https://specstream.ai/data/businesses/scandinavian-restaurants/united-states)
